Charles River Laboratories (CRL) Peer Comparison
$288.24
$-3.26
(-1.12%)
As on 31-Aug-2026 16:00EDT
Market cap
$14,038 Mln
Revenue (TTM)
$3,999 Mln
P/E Ratio
--
P/B Ratio
4.9
Div. Yield
0 %
Edit
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
14,038 | 21,673 | 11,346 | 10,953 | 8,904 |
Revenue ($ Mln) |
3,999 | 1,183 | 1,215 | -- | -- |
Net Profit ($ Mln) |
-238.46 | -453.44 | 181.86 | -856.09 | -1,064.26 |
Net Margin (%) |
-5.96 | -38.33 | 14.97 | -- | -- |
RoE (%) |
-8.01 | -- | 9.03 | -153.01 | -39.10 |
Price to Earnings |
-- | -- | 62.37 | -- | -- |
Price-To-Book |
4.88 | 55.67 | 5.39 | 18.16 | 3.30 |
Income Statement ($ Mln)
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
3,998.99 | 1,183.11 | 1,215.04 | 0.00 | 0.00 |
|
Cost of Revenue
|
2,709.65 | 413.95 | 415.97 | 0.05 | 0.87 |
|
Gross Profit
|
1,225.57 | 633.01 | 790.27 | -0.11 | -- |
|
Operating Expenses
|
795.54 | 1,239.42 | 547.18 | 874.79 | 1,164.43 |
|
Operating Profit (EBIT)
|
493.80 | -470.26 | 251.89 | -874.79 | -1,165.29 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-183.67 | -454.47 | 240.68 | -856.04 | -1,064.26 |
|
Provision for Tax
|
52.63 | -1.03 | 58.82 | 0.00 | 0.00 |
|
Profit after Tax (Net Income)
|
-238.46 | -453.44 | 181.86 | -856.09 | -1,064.26 |
|
Minority Interest
|
-2.16 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
-222.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,839.64 | -222.87 | 2,108.22 | 629.98 | 2,757.94 |
|
Minority Interest
|
-2.16 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
3,508.87 | 1,796.20 | 314.81 | 18.64 | 108.94 |
|
Current Liabilities
|
1,134.75 | 338.96 | 163.70 | 103.57 | 271.28 |
|
Total Liabilities
|
7,135.42 | 2,013.66 | 2,557.87 | 557.50 | 3,045.97 |
Assets ($ Mln)
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6,003.04 | 547.66 | 1,842.33 | 31.61 | 1,585.49 |
|
Current Assets
|
1,529.11 | 1,364.64 | 744.40 | 720.58 | 1,552.67 |
|
Total Assets
|
7,135.42 | 2,013.66 | 2,557.87 | 557.50 | 3,045.97 |
|
Total Debt*
|
3,027.69 | 1,697.01 | 289.09 | 20.38 | 115.45 |
|
Net Current Assets
|
394.36 | 1,025.68 | 0.00 | 617.01 | 1,281.39 |
Cashflow ($ Mln)
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
737.65 | -184.76 | 287.56 | -239.67 | -655.58 |
|
Cash Flow from Investing Activities
|
-209.32 | -627.20 | -35.18 | -129.37 | 437.35 |
|
Cash from Financing Activities
|
-536.73 | 671.13 | -253.91 | 458.31 | 2.01 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-2.33 | -29.66 | 3.03 | -263.03 | -24.37 |
|
ROE (%)
|
-8.01 | 348.42 | 8.83 | -153.01 | -39.10 |
|
ROA (%)
|
-2.76 | -23.73 | 6.00 | -173.90 | -30.99 |
|
EBIT Margin (%)
|
-1.94 | -38.01 | 20.25 | -- | -- |
|
Net Margin (%)
|
-5.96 | -38.33 | 14.97 | -- | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | -- | -- |
Growth Ratios
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.74 | 42.74 | -0.38 | -- | -- |
|
EBIT Growth (%)
|
-178.82 | -9.76 | 130.05 | -10.72 | -113.26 |
|
Net Profit Growth (%)
|
-244.47 | -9.57 | 147.77 | -130.47 | -94.39 |
|
EPS Growth (%)
|
-266.27 | -4.67 | 155.17 | -122.88 | -81.42 |
|
Book Value Growth (%)
|
-13.87 | 31.44 | 9.00 | 321.10 | -15.46 |
Valuation Ratios
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-68.02 | -31.57 | 109.18 | -12.42 | -8.19 |
|
Price / Book Value
|
3.10 | -132.33 | 4.18 | 27.41 | 2.34 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
30.84 | -36.51 | 38.25 | -11.94 | -6.67 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.92 | -6.74 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | -0.12 | 0.01 | 0.01 | 0.00 |
|
Current Ratio
|
1.35 | 4.03 | 4.55 | 6.96 | 5.72 |
|
Quick Ratio
|
1.04 | 3.71 | 3.35 | 6.96 | 5.72 |
|
Interest Coverage
|
-0.73 | -93.37 | 45.53 | -- | -- |
Operating Efficiency Ratios
| Charles River Laboratories (CRL) | Guardant Health (GH) | Bio-Techne Corp (TECH) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.80 | 12.19 | 17.83 | -- | -- |
|
Asset Turnover
|
0.46 | 0.62 | 0.40 | 0.00 | 0.00 |
|
Receivable days
|
65.03 | 46.14 | 67.12 | -- | -- |
|
Inventory Days
|
37.81 | 82.13 | 157.03 | -- | -- |
|
Payable days
|
18.93 | 48.66 | 26.92 | 31,626.28 | -- |
|
Cash Conversion Cycle
|
83.91 | 79.61 | 197.23 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
